Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05053815
Other study ID # TRHC-PACE-PGX-2021-001
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date November 2, 2021
Est. completion date March 1, 2024

Study information

Verified date September 2022
Source Tabula Rasa HealthCare
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Tabula Rasa HealthCare (TRHC), doing business as CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services. CareKinesis utilizes medication decision support tools and pharmacists certified in geriatrics to provide pharmacy services for various healthcare organizations including PACE organizations. Program of All-inclusive Care for the Elderly (PACE) is a Medicare-Medicaid program that provides comprehensive medical and supportive services to individuals >55 years of age who are certified by their state as needing nursing home care. As an alternative to institutionalization, PACE helps these individuals live safely in their community. The aim of PACE is to improve overall quality of life in four domains (physical, psychological, social, and spiritual) using a multidisciplinary approach. In the United States, the vast majority of PACE organizations collaborate with one pharmacy to dispense drugs, in addition to other pharmacy services, for their population of participants. Presently, CareKinesis services approximately 140 PACE sites, across the country. As a national PACE pharmacy provider since 2011, CareKinesis focuses on improving medication regimens to reduce medication-related risks while enhancing economic, clinical and humanistic outcomes.


Description:

Pharmacist-led pharmacogenomics (PGx) clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by CareKinesis d/b/a Tabula Rasa HealthCare. This project aims to include patients enrolled in the PACE organization who received PGx testing. PGx testing was performed by one of several contracted PGx vendors with TRHC (e.g., Corriel, CQuentia, OneOme) at the time. Upon return from the laboratory, PGx results were integrated into TRHC's proprietary Clinical Decision Support System (Medication Risk Mitigation™ Matrix, CareKinesis, Moorestown, NJ) that guides pharmacists to identify DDIs, DGIs, and DDGIs. As part of this workflow, clinical pharmacists utilized PGx results combined with a comprehensive DDI review (via PGx consult, medication safety review, and/or polypharmacy call) to inform their recommendations to PACE prescribers to address medication problems, including those related to DDIs, DGIs, and/or DDGIs (drug-induced phenoconversion). Upon reviewing the pharmacist's recommendation(s) and based on their clinical assessment, PACE prescribers decided whether to implement the recommended changes. This current study plans to collect data retrospectively from the past six years (2016-2021) on specific PGx test results, genotype-guided and interacting drugs, and recommendations, in order to look for any patterns that may help optimize the process of PGx consultation and/or PGx-guided recommendations, with the ultimate goal of reducing adverse drug events and improving patient outcomes.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 1500
Est. completion date March 1, 2024
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient received PGx testing; and 2. Patient enrolled in a PACE organization when PGx test results were returned; and 3. PACE organization contractually received pharmacy services from CareKinesis upon PGx return of results. Exclusion Criteria: a) Patient did not receive PGx test results.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pharmacogenomic Testing
Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.

Locations

Country Name City State
United States Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute Orlando Florida

Sponsors (1)

Lead Sponsor Collaborator
Tabula Rasa HealthCare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the value of PGx testing for pharmacogenes and subsequent CDSS-informed, pharmacist-led PGx consultation and its impact on recommendations and prescribing decisions. Quantitative 1 year
Primary Measure PGx-guided interventions on improvement of therapy response. Quantitative 1 year
Primary Measure PGx-guided interventions on improvement of adverse drug events. Quantitative 1 year
See also
  Status Clinical Trial Phase
Completed NCT03688542 - Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module N/A
Completed NCT02545257 - Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care N/A
Withdrawn NCT01932632 - Medication Minimization for Long-term Care Residents N/A
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Active, not recruiting NCT04181879 - Appropriate Polypharmacy in Older People in Primary Care N/A
Not yet recruiting NCT03283735 - Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal N/A
Completed NCT02918058 - Reducing Post-discharge Potentially Inappropriate Medications Among Older Adults N/A
Completed NCT03655405 - Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents N/A
Completed NCT04575155 - Development & Pilot of the Technology-Enabled Alliance for Medication Therapy Management N/A
Withdrawn NCT05816967 - Rationalisation of Polypharmacy by the RASP-instrument and Discharge Counselling of Geriatric Inpatients N/A
Completed NCT05616689 - Bundled Hyperpolypharmacy Deprescribing N/A
Terminated NCT04055896 - Team Approach to Polypharmacy Evaluation and Reduction in a Long-Term Care Setting N/A
Active, not recruiting NCT03052192 - Biological Aging, Medication, Malnutrition and Inflammation Among Acutely Ill and Healthy Elderly.
Completed NCT02866799 - Multi-PAP: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy N/A
Completed NCT01732302 - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients N/A
Active, not recruiting NCT04585191 - Reducing Treatment Risk in Older Adults With Diabetes N/A
Active, not recruiting NCT04120480 - Effectiveness of PGx Testing N/A
Recruiting NCT05609981 - Optimising Medication With Focus on Deprescribing in Frail Older People With Multidose Drug Dispensing Systems N/A
Recruiting NCT05501223 - Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic N/A
Completed NCT05628181 - A Patient-facing Tool to Reduce Opioid-Psychotropic Polypharmacy in People Living With Dementia (PLWD) N/A